Market Overview

Mylan Is 'Comfortable Moving Forward' With Acquisition Of Sweden-Based Meda


Mylan NV (NASDAQ: MYL) announced in early February it had entered into an agreement to acquire Sweden-based Meda.

Following the breakup of Pfizer Inc. (NYSE: PFE)'s proposed merger with Allergan plc Ordinary Shares (NYSE: AGN), investors are focusing in on other active M&A deals within the sector.

Bloomberg reported on Wednesday that Mylan remains "comfortable moving forward" with its proposed $7.2 billion acquisition of Meda.

Related Link: Investors Applaud Ending Of Pfizer-Allergan Deal

Mylan moved its headquarters from Pittsburgh to the Netherlands last year following its acquisition of Abbott Laboratories' generic drug business in international markets including Europe.

Shares of Mylan were trading higher by nearly 5 percent early Wednesday afternoon.


Related Articles (MYL)

View Comments and Join the Discussion!

Posted-In: abbott laboratoriesBiotech M&A News Health Care Global Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at